FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner Pharmacy Purchasing & Products Magazine BPC 157 Banned: Key Facts on the Latest FDA Decision The Blacklisting of Peptides The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Why the FDA Is Paying More Attention to 503A & 503B Pharmacies If you've been watching the compounding space, especially around GLP 1s and peptides, you've probably noticed something. The FDA is paying